当前位置: X-MOL 学术J. Contemp. Brachyther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Plaque brachytherapy in iris and iridociliary melanoma: a systematic review of efficacy and complications
Journal of Contemporary Brachytherapy ( IF 1.4 ) Pub Date : 2021-02-17 , DOI: 10.5114/jcb.2021.103586
Saeed Karimi 1, 2 , Amir Arabi 1, 2 , Toktam Shahraki 1, 2
Affiliation  

Introduction
To evaluate the efficacy and vision-threatening complication rate of plaque brachytherapy with iodine-125 (125I), palladium-103 (103Pd), and ruthenium-106 (106Ru) for treatment of iris and iridociliary melanoma.

Material and methods
A literature review was done based on results yielded from searching PubMed, Embase, and Cochrane database, using following key words: iris melanoma, iridociliary melanoma, brachytherapy, iodine-125 brachytherapy, palladium-103 brachytherapy, and ruthenium-106 brachytherapy. Initially, relationships between mean radiation dose to apex and local recurrence and complication rate were analyzed, and then, a comparison was performed between 125I, 103Pd, and 106Ru studies.

Results
Twelve retrospective and prospective studies were selected, with 491 patients treated primarily with plaque brachytherapy. The range of radiation dose to tumor apex were from 84 to 151.5 Gy. Ranges of mean and median of follow-up time were from 27 to 96 months. Local recurrence rate following brachytherapy ranged from 0 to 8%. A decrease in the average study dose was not associated with an increased local recurrence or metastasis rate (p = 0.373 and 0.195, respectively); however, an increase in radiation dose was associated with higher radiation-related cataract and glaucoma (p < 0.05). The rate of post-treatment glaucoma was higher in studies with 125I plaque brachytherapy (p = 0.004).

Conclusions
For brachytherapy of iris and iridociliary melanoma, in a range of 84 to 150 Gy, an increase in radiation dose may increase the risk of complications, while the tumor control rate does not change.



中文翻译:

虹膜和虹膜虹膜黑色素瘤的斑块近距离治疗:疗效和并发症的系统评价

引言
评价使用碘125(125I),钯103(103Pd)和钌106(106Ru)进行斑块近距离放射治疗虹膜和虹膜睫状黑素瘤的疗效和威胁视力的并发症发生率。

材料和方法
根据检索PubMed,Embase和Cochrane数据库的结果,使用以下关键词进行文献综述:虹膜黑素瘤,虹膜睫状黑素瘤,近距离放射治疗,碘125近距离放射治疗,钯103近距离放射治疗和钌106近距离放射治疗。 。最初,分析了平均辐射剂量至根尖与局部复发率和并发症发生率之间的关系,然后比较了125I,103Pd和106Ru研究。

结果
选择了12项回顾性和前瞻性研究,其中491例患者主要接受了斑块近距离放射治疗。肿瘤顶点的辐射剂量范围为84至151.5 Gy。随访时间的平均值和中位数范围为27到96个月。近距离放射治疗后局部复发率在0%至8%之间。平均研究剂量的减少与局部复发或转移率的增加无关(分别为p = 0.373和0.195)。然而,辐射剂量的增加与更高的辐射相关性白内障和青光眼有关(p <0.05)。在125I斑块近距离放射治疗的研究中,治疗后的青光眼发生率更高(p = 0.004)。

结论
对于虹膜和虹膜虹膜黑色素瘤的近距离放射治疗,范围在84至150 Gy之间,放射剂量的增加可能会增加发生并发症的风险,而肿瘤控制率不会改变。

更新日期:2021-02-17
down
wechat
bug